We are live on ! Find out more
ENGN icon

enGene Therapeutics
ENGN

37 hedge funds and large institutions have $279M invested in enGene Therapeutics in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more capital invested

Capital invested by funds: $147M → $279M (+$132M)

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

3% more funds holding

Funds holding: 36 → 37 (+1)

0.74% more ownership

Funds ownership: 79.07% → 79.81% (+0.74%)

13% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 8

Holders
37
Holders Change
+1
Holders Change %
+2.78%
% of All Funds
0.49%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
7
Increased
7
Reduced
8
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
B
Braidwell
Connecticut
+$10.3M
2
PA
Perceptive Advisors
New York
+$9.56M
3
FLSM
Frazier Life Sciences Management
California
+$5.28M
4
MB
MPM BioImpact
Massachusetts
+$2.42M
5
Morgan Stanley
Morgan Stanley
New York
+$376K

Top Sellers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
-$10.6M
2
Bank of America
Bank of America
North Carolina
-$6.19M
3
Goldman Sachs
Goldman Sachs
New York
-$3.43M
4
O
OrbiMed
New York
-$2.47M
5
BOCH
Blue Owl Capital Holdings
New York
-$2.05M
Name Holding Trade Value Shares
Change 		Change in
Stake
FIS
1
FCPM III Services
Netherlands
$65.8M – – –
VA
2
VR Adviser
New York
$34.5M – – –
KCM
3
Kynam Capital Management
New Jersey
$34.1M – – –
BOCH
4
Blue Owl Capital Holdings
New York
$22.4M -$2.05M -450,000 -12%
CAM
5
Cormorant Asset Management
Massachusetts
$15.9M – – –
B
6
Braidwell
Connecticut
$15.5M +$10.3M +2,266,319 New
DTC
7
Deep Track Capital
Connecticut
$15.3M -$10.6M -2,318,222 -51%
PA
8
Perceptive Advisors
New York
$14.3M +$9.56M +2,097,236 New
Point72 Asset Management
9
Point72 Asset Management
Connecticut
$8.25M +$456 +100 +0%
FLSM
10
Frazier Life Sciences Management
California
$7.9M +$5.28M +1,157,380 New
Franklin Resources
11
Franklin Resources
California
$7.09M – – –
Adage Capital Partners
12
Adage Capital Partners
Massachusetts
$6.83M – – –
SOCM
13
SR One Capital Management
Pennsylvania
$5.11M – – –
Bank of America
14
Bank of America
North Carolina
$4.42M -$6.19M -1,358,516 -68%
MB
15
MPM BioImpact
Massachusetts
$3.62M +$2.42M +530,299 New
OFM
16
Omega Fund Management
Massachusetts
$3.6M – – –
SFM
17
Sphera Funds Management
Israel
$3.45M – – –
Morgan Stanley
18
Morgan Stanley
New York
$2.97M +$376K +82,523 +23%
VPC
19
Vestal Point Capital
New York
$2.53M – – –
Marshall Wace
20
Marshall Wace
United Kingdom
$2.35M – – –
Goldman Sachs
21
Goldman Sachs
New York
$1.01M -$3.43M -751,484 -84%
AAA
22
Affinity Asset Advisors
New York
$526K – – –
Citadel Advisors
23
Citadel Advisors
Florida
$399K +$161K +35,327 +153%
Northern Trust
24
Northern Trust
Illinois
$207K -$12.5K -2,731 -8%
Geode Capital Management
25
Geode Capital Management
Massachusetts
$198K – – –
1
2

ENGN Hedge Fund Activity: Q3 2025 in Review

37 of the 7,625 institutional investors tracked by Wall St. Rank reported a position in enGene Therapeutics (ENGN) for Q3 2025, worth a combined $279M — up 90% from $147M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ENGN positions and 6 closed out — a net gain of 1 holder — while 7 added to existing stakes and 8 trimmed.

The largest buyer was Braidwell, opening a new position worth an estimated $10.3M. The largest seller was Deep Track Capital, cutting an estimated $10.6M.

  • 37 institutional investors held enGene Therapeutics (ENGN) as of Q3 2025, up from 36 in Q2 2025.
  • Funds reported $279M of enGene Therapeutics stock for Q3 2025, up 90% quarter-over-quarter.
  • 7 funds opened new enGene Therapeutics positions in Q3 2025 and 6 closed out, a net change of +1 holder.
  • The largest enGene Therapeutics buyer in Q3 2025 was Braidwell, an estimated $10.3M added.
  • The largest enGene Therapeutics seller in Q3 2025 was Deep Track Capital, an estimated $10.6M sold.

Based on aggregated 13F filings for Q3 2025.